Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

EBR
February 24th, 2023

EBR Systems - Pivotal Results Due Q2

EBR Systems (EBR: $0.60) is a relatively new biotech on the ASX, having listed in November 2021 at $1.08 per share, raising $110 million. It is developing the world's first and only wireless electronic heart pacing system for the left ventricular, called WiSE. It is being trialled with commercially available right ventricle pacers (both with leads and wireless) to offer a novel cardiac resynchronisation therapy (CRT).

BradOConnor_Final720x390
February 24th, 2023

Cogstate Acquisition Discussions Halted

Cogstate (CGS: $1.18) came close to being acquired in the recent weeks with discussions with an interested group beginning in December and negotiations ending last week.

33251anteristechnologiespng
February 24th, 2023

Anteris Technologies Raises $35 Million

Aortic heart valve company Anteris Technologies (AVR: $21.71) has completed a $35 million capital raise, conducted at $24 per share. Investors also received a free two-year option to buy an additional share at $29.

aroa
February 3rd, 2023

Aroa Biosurgery on Track with Sales and Move to Profitability

Aroa Biosurgery (ARX: $1.15) delivered another consistent quarter of growth. Net cash receipts were up 88% over the PCP to NZ$17 million for the quarter, and up 83% over the PCP for the last nine months to NZ$42 million.

 

 

biogene
February 3rd, 2023

Bio-Gene Strikes Significant Deal with STK Bio-Ag Technologies

Insecticide development company Bio-Gene Technology (BGT: $0.096) has signed a development and product access deal with Israeli group STK Bio-Ag Technologies.

376cc45a3f7fe557c56981440c937630
December 23rd, 2022

Top 6 Stock Picks for 2023

Going into to 2023, Pharmaxis will have two Phase II study results to report. One is with PXS-6302 in the treatment of scars, and the second is with PXS-5505 for the treatment of myelofibrosis.

1639524692803
December 23rd, 2022

2023 Top Six Pick - Aroa Biosurgery: A Defensive Growth Stock for Investors

Wound healing products company Aroa Biosurgery (ARX: $1.10) is proving to be a very predictable performer, meeting or exceeding its sales forecasts.

For the first half of its 2023 financial year (ending 30 September) the company achieved a 44% growth in sales to NZ$29 million. The company is forecasting to be EBITDA neutral by the end of March next year.

adalta2
December 19th, 2022

Adalta Returns to IV Formulation for AD-214

Last year novel antibody company Adalta (1AD: $0.044) announced that it would be moving to develop an inhaled formulation of its lead drug candidate, AD-214. This followed preclinical studies that showed high accumulation of the compound in the liver, although no liver toxicity was observed in patients in the Phase I study.

1623118494675DR_NINA_WEBSTER
December 19th, 2022

Dimerix Completes Recruitment of First Stage in Phase III Study

Dimerix (DXB: $0.17) has completed recruitment of the first part of its Phase III study in the kidney disease FSGS (focal segmental glomerulosclerosis) with 72 patients. It will now move into the second part where an additional 72 patients will be treated for 35 weeks with placebo or active drug.

cogstate
December 19th, 2022

Lecanemab Data Presented; Positive News for Cogstate

The Phase III trial data on the emerging Alzheimer's disease drug lecanemab has been published in the New England Journal of Medicine and was presented at the recent Alzheimer's disease conference, CTAD, held in San Francisco, by Dr Sharen Cohen. Dr Cohen was an investigator on the Phase III Eisai/Biogen Alzheimer's disease study and co-authored the paper that was published.

The data is of interest to Cogstate (CGS: $1.80) and investors as Cogstate's core business is in conducting Alzheimer's disease studies, and its blue sky is the use of its cognitive diagnostic tool, licensed by Eisai, to help identify patients should an effective drug treatment for Alzheimer's disease become available.

Pages